🔎 Trials Near Me

Pradžia › Difuzinė didelė B ląstelių limfoma › Oregon

Difuzinė didelė B ląstelių limfoma klinikiniai tyrimai Oregon

15 tyrimai dėl Difuzinė didelė B ląstelių limfoma ieško dalyvių vietose Oregon.

Miestai Oregon

Oficialus tyrimo tekstas (anglų kalba)

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • Oncology Associates of Oregon, Eugene
  • Oregon Health and Science University, Portland
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06500273

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06649812

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  • Providence Portland Medical Center ( Site 0120), Portland
  • Providence Oncology and Hematology Clinic Westside ( Site 0179), Portland
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06890884

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

  • OHSU Knight Cancer Institute, Portland
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT06784167

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Oregon Health & Science University (OHSU), Portland
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07226843

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Oregon Health and Science University ( Site 1004), Portland
Renkami dalyviai1/2 fazė
6 Months – 25 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT06395103

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  • Oncology Associates of Oregon, P.C, Eugene
  • Providence Portland Medical Center, Portland
  • Providence St. Vincent Medical Center, Portland
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-11 · NCT06806033

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Oregon Health & Science University, Portland
Renkami dalyviai1/2 fazė
Amžius nuo 13 iki 90 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06533579

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

  • Oregon Health and Science University Knight Cancer Institute, Portland
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-05 · NCT06116110

DALY II USA/ MB-CART2019.1 for DLBCL

  • Oregon Health and Science University Knight Cancer Institute, Portland
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-13 · NCT04792489

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

  • OHSU Knight Cancer Institute, Portland
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-07-07 · NCT06249191

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • Providence Newberg Medical Center, Newberg
  • Providence Willamette Falls Medical Center, Oregon City
  • Providence Portland Medical Center, Portland
  • ir dar 2
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-02 · NCT05633615

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  • Providence Newberg Medical Center, Newberg
  • Providence Willamette Falls Medical Center, Oregon City
  • Providence Portland Medical Center, Portland
  • ir dar 1
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-10-20 · NCT05890352

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • Oregon Health & Science University, Portland
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-10-02 · NCT05780034

Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.